Differential abundance of CK1α provides selectivity for pharmacological CK1α activators to target WNT-dependent tumors
Bin Li(China Pharmaceutical University), David J. Robbins(Georgetown University), Chen Shen(Nanjing University of Science and Technology), Luisana Astudillo(University of Miami), Dennis Liang Fei(University of Miami), Melanie H. Cobb(The University of Texas Southwestern Medical Center), Leif R. Neitzel(Vanderbilt University Medical Center), Curtis A. Thorne(Vanderbilt University Medical Center), Marcy L. Guerra(StemSynergy Therapeutics (United States)), Kellye C. Kirkbride(StemSynergy Therapeutics (United States)), Jezabel Rodríguez‐Blanco(Medical University of South Carolina), Darren Orton(Vanderbilt University), Anthony J. Capobianco(General Motors (Poland)), Laurence R. Sands(University of Miami), Thomas Doundoulakis(StemSynergy Therapeutics (United States)), Ethan Lee(Johns Hopkins University), Julia Zaias(University of Miami), Xi Chen(University of Miami), Zhiqiang Wang, Ke Jin(Sichuan University), Dao M. Nguyen(University of Miami), Jun Long(Zhujiang Hospital), Floriano Marchetti(University of Miami), María T. Abreu(Icahn School of Medicine at Mount Sinai)
Cited by 49
Related Papers
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2019|1.2k
The structure of the G protein heterotrimer Giα1β1γ2
|Cell|1995|1.1k